Treatment for adults with relapsed or refractory diffuse large B-cell lymphoma
Gilead Sciences announced that the National Institutes of Health (NICE) has recommended Yescarta (axicabtagene ciloleucel) for routine commissioning in NHSs across the UK.
This is for certain adults with certain forms of lymphoma, particularly diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma who have already been treated with two or more systemic therapies. It is concerned with the treatment of patients with sexually transmitted lymphoma (PMBCL).
CAR T-cell therapy is currently an approved patient treatment for patients with certain advanced blood cancers. CAR T-cell therapy, on the other hand, manipulates an individual patient’s own immune cells to detect, target, and destroy cancer cells.
Dr Véronique Walsh, Vice President, Gilead Sciences UK and Ireland, commented:
“This news comes at a time when new hospitals are preparing to offer CAR T-cell therapy, and we are confident that medical professionals at these centers will have this treatment as an important option for their patients. means.”
Dr Graham Collins, Consultant Hematologist at Oxford University Hospitals NHS Foundation Trust, concludes:
“Today’s news is encouraging because it shows that these therapies are meeting expectations for patients with aggressive lymphoma, even in a real-world setting. This means that some patients who have undergone chemotherapy may face a different outlook on prognosis.”
Through the Cancer Drugs Fund in 2018, the UK became the first country in Europe to provide access to CAR T-cell therapy to treat these blood cancers. Since then, over 500 of her patients in the UK have received axicabtagene ciloleucel.
